#France #Toulouse #Pierre Fabre #Avène #BotDesign

Exploring AI's Potential in Dermo-Cosmetic Clinical Studies

In an exciting development for the dermo-cosmetic industry, Pierre Fabre Laboratories has embarked on a groundbreaking project to harness the power of artificial intelligence (AI) for clinical studies. Their renowned brand, Avène, known for its leadership in the French pharmacy circuit, is set to lead the charge in utilizing AI to strengthen the robustness of its clinical studies in treating acne.

A Significant Step Forward

In 2026, Avène plans to conduct a comparative clinical study to evaluate the effectiveness of its latest skincare product, Avène Cleanance Comedomed+, designed for patients with acne-prone skin. This study will focus on adults suffering from severe to very severe acne who have undergone oral isotretinoin treatment. Avène aims to be the first to incorporate AI into clinical research within the dermo-cosmetic field.

The Study's Unique Design

The clinical trial will consist of two patient groups: one group will receive the Avène Cleanance Comedomed+ treatment following isotretinoin, and the other will receive a placebo. To boost the statistical power and reliability of the results, the collaboration with BotDesign will enable an increase in the number of patients included in the study. By employing AI technologies, they plan to generate synthetic patient data, effectively augmenting the sample size in both groups by up to 500 additional patients.

This innovative approach, validated by the scientific community, was recently presented at the International Congress of Dermatology in Rome. A scientific publication detailing this methodology is currently in progress and is expected to enhance the credibility of the clinical study results, set to be revealed in December 2026.

Integrating AI with Comprehensive Care

This pioneering study is not only scientifically ambitious but also aligns with Pierre Fabre's strategy of "Supportive Care," which focuses on enhancing patient care beyond traditional therapeutic approaches. Dr. Gautier Doat, the Medical Director of Avène, emphasizes that their medical expertise positions them uniquely to understand patient needs and conditions. This dual approach aims to merge dermo-cosmetic treatments with medicinal therapies, leading to innovative solutions that can prolong and enhance treatment effects.

A Closer Look at Acne Prevalence

Acne is a significant concern for many individuals, with a recent study by Pierre Fabre indicating that almost half of the population over the age of 16 is affected. This underscores the pressing need for effective treatments and innovative research approaches in this area.

About Pierre Fabre Laboratories

Pierre Fabre Laboratories stands as the second-largest dermo-cosmetics company worldwide and a prominent player in the European pharmaceutical industry. Their extensive product portfolio includes various international brands such as Eau Thermale Avène, Ducray, Klorane, A-Derma, and many others. The Laboratories focus on five key therapeutic areas, including oncology, dermatology, rare diseases, chronic conditions, and family health, significantly investing in research and development. The company's commitment to social responsibility is evident in its ownership structure, where a humanitarian foundation ensures long-term independence and social contributions.

In conclusion, Pierre Fabre's initiative to explore AI for clinical studies symbolizes a promising future in dermatological research and patient care. The outcome of this innovative project may initiate a new era in the dermo-cosmetic industry, paving the way for advanced treatment protocols that prioritize patient well-being and effective skincare solutions.